Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

INTRODUCTION: New regimens involving direct-acting antiviral agents (DAAs) have recently been approved for the treatment of hepatitis C virus (HCV) genotype 4 (GT4). The current study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Moneim, Adel, Abood, Alaa, Abdel-Gabaar, Mohamed, Zanaty, Mohamed I., Ramadan, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185926/
https://www.ncbi.nlm.nih.gov/pubmed/30324144
http://dx.doi.org/10.5114/ceh.2018.78123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185926/
https://www.ncbi.nlm.nih.gov/pubmed/30324144
http://dx.doi.org/10.5114/ceh.2018.78123

Ejemplares similares